Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.

about

Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.

Item

http://www.wikidata.org/entity/Q49548756

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Fabry disease under enzyme rep ...... efficacy of different dosages.

@en

Fabry disease under enzyme rep ...... efficacy of different dosages.

@nl

type

Item

label

Fabry disease under enzyme rep ...... efficacy of different dosages.

@en

Fabry disease under enzyme rep ...... efficacy of different dosages.

@nl

prefLabel

Fabry disease under enzyme rep ...... efficacy of different dosages.

@en

Fabry disease under enzyme rep ...... efficacy of different dosages.

@nl

P1476

Fabry disease under enzyme rep ...... efficacy of different dosages.

@en

P2093

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

Claudia Sommer

http://www.w3.org/2001/XMLSchema#string

Daniela Blaschke

http://www.w3.org/2001/XMLSchema#string

Eva Brand

http://www.w3.org/2001/XMLSchema#string

Frank Weidemann

http://www.w3.org/2001/XMLSchema#string

Johannes Krämer

http://www.w3.org/2001/XMLSchema#string

Jörg Stypmann

http://www.w3.org/2001/XMLSchema#string

Malte Lenders

http://www.w3.org/2001/XMLSchema#string

Sima Canaan-Kühl

http://www.w3.org/2001/XMLSchema#string

Stefan Störk

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.

Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.

Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.

P31

scholarly article

P356

10.1093/NDT/GFX319

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Nurcan Üçeyler

Peter Nordbeck

P577

2017-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29186537

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy